NAD metabolism is crucial for tumor microenvironment (TME) and it has been reported that NAD+ replenishment combined with PD-1/PD-L1 antibody provides a promising therapeutic strategy for immunotherapy-resistant tumors (46) and supplement of NAD+ could boost T cell-based immunotherapy (47). The gene discussed is CD274; the disease is neoplasm.